Grupo de investigacións biomédicas
GIBIOMED
Eli Lilly and Company
Indianapolis, EE. UU.Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (7)
2024
-
Improved guidance is needed to optimise diagnostics and treatment of patients with thyroid cancer in Europe
Endocrine, Vol. 83, Núm. 3, pp. 585-593
2017
-
Gefitinib and EGFR gene copy number aberrations in esophageal cancer
Journal of Clinical Oncology, Vol. 35, Núm. 20, pp. 2279-2287
2014
-
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): A phase 3, multicentre, double-blind, placebo-controlled randomised trial
The Lancet Oncology, Vol. 15, Núm. 8, pp. 894-904
2012
-
Mice lacking δ-opioid receptors resist the development of diet-induced obesity
FASEB Journal, Vol. 26, Núm. 8, pp. 3483-3492
2010
-
κ-Opioid receptors control the metabolic response to a high-energy diet in mice
FASEB Journal, Vol. 24, Núm. 4, pp. 1151-1159
2007
-
The central melanocortin system directly controls peripheral lipid metabolism
Journal of Clinical Investigation, Vol. 117, Núm. 11, pp. 3475-3488
1997
-
Leptin inhibits in vitro hypothalamic somatostatin secretion and somatostatin mRNA levels
Endocrinology, Vol. 138, Núm. 12, pp. 5641-5644